The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
still about. Assuming it is the same person, they must have had a notifiable position at some point as it has been daily and been going on for ages. Seem content to feed them with in a certain range.
Block seller still about. Wow he really must have had a load to sell. Can only sell once though.
Someone exiting in £2k chunks
This is all rather tiresome. You have your investing/trading strategy - we all do, but we have been here previously with your volte face. You may be correct with your assessment, indeed Morocco is somewhat opaque as to time scales and Trinidad may be weeks away, that said the company may be working on matters we are unaware of. In the grand scheme of things it really matter not. Most LTH will doubtless invest more if 2's arrive-I certainly would and I feel confident you will also increase your stated substantial holding as well - indeed maybe a TR/1 is in the offing?
sp performance over last few months - amplified by almost 11% decline in last 2 trading days. Given the fundamentals of the Company it needs to address this issue somewhat more pro actively.
Not too much buying appetite today, coupled with ready seller in the wings softens the SP. May go lower before buyers react, but now needs some impetus from the BoD to provide firm timelines on Morocco.
how the enforced delays have actually played out well for PRD, by the time we have a date for Morocco drill and the herd get wind there shouldn't be much to hold us back on build up to spud. Of Course Trinidad may come in beforehand. News beginning to stack up.
lots of sells printed after hours. SP held up rather well. More churn but there will come a point when the MM's will have to work a bit harder.
Bit of good news. Greta buy in price. Hopefully some of the shorts will start closing.
will be strong sub 4. Great progress made against a wall of flippers. As we move into the 4's more resistance , at various levels, will be encountered. Therefore, the company will need to be proactive and savvy in their market announcements. The morocco drill is now nicely primed.
nice reversal, in a difficult market.
Nice bit of movement and volume this morning. Coming to the attention of more PI's. Strange how the delayed drill due to the virus has now presented a lovely build up, now overhang is diminished, into the opening up of the Morocco and subsequent spud this summer.
Tend to agree that virus induced delays have helped clear the decks for a nice run up to spud. Still believe there is a sizeable chunk of the 2p placing remaining, but some may be holding for higher up. This stock is generally not over exposed to PI's, but with the three exiting assets, each making progress and funding in place, the gains to be made should be v good. Expect steady rise over coming weeks/months. Good to time to be building as still below larger 4p placing price.
Let the main stream press cover the news and see the reaction. This test is the most talked about as everyone wants to see if they have had the virus.
Well, interesting RNS.
to release RNS, but indicative of the poor communication and regard for shareholders.
at its toughest, though not unsurprising.
set up lovely for Morocco reopening and going forward, news from Trin. Sense some forward selling from 2 placing, which has a week before they are issued. All in all this is primed to have a good run into spud.
let this play out. Point 4.
- The net proceeds of the Fundraising will be used to
o Maximise available Covid-19 opportunities including accelerating the development of both a seasonal coronavirus and a Covid-19 virus challenge study model to capitalise upon Group's inbound demand from Covid-19 vaccine developers globally. These challenge study models have the ability to speed up the development of a vaccine by 2-3 years;
o Ramp up Covid-19 antiviral testing to the Group's current capacity for 3,000 tests per day;
o Expand existing laboratory testing services to 3rd party pharmaceutical and biotech companies in line with our strategy of becoming a leading services provider to the growing viral, and respiratory diseases sector of the pharmaceutical industry; and
o Strengthen the balance sheet to enable the Group to take advantage of the significant and growing opportunities the Board believes are available.
Price coming down. Buy @2.5